Clinical Utility of Olaparib in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Review of Current Evidence and Patient Selection
Alexis LeVee,Ching Ying Lin,Edwin Posadas,Robert Figlin,Neil A Bhowmick,Dolores Di Vizio,Leigh Ellis,Charlos J Rosser,Michael R Freeman,Dan Theodorescu,Stephen J Freedland,Jun Gong,Charles J Rosser
DOI: https://doi.org/10.2147/OTT.S315170
IF: 4
2021-09-15
OncoTargets and Therapy
Abstract:Alexis LeVee, 1 Ching Ying Lin, 1 Edwin Posadas, 1 Robert Figlin, 1 Neil A Bhowmick, 1 Dolores Di Vizio, 2 Leigh Ellis, 1 Charlos J Rosser, 3 Michael R Freeman, 2 Dan Theodorescu, 2 Stephen J Freedland, 3, 4 Jun Gong 1 1 Department of Medicine, Division of Hematology and Oncology, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA; 2 Department of Surgery, Division of Cancer Biology and Therapeutics, Biomedical Sciences, and Pathology and Laboratory Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA; 3 Department of Surgery, Division of Urology, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA; 4 Section of Urology, Durham VA Medical Center, Durham, NC, USA Correspondence: Jun Gong Email Metastatic castration-resistant prostate cancer (mCRPC) is an aggressive and fatal disease with a median survival of 36 months. With the advent of genetic sequencing to identify individual genomic profiles and acquired tumor-specific pathways, targeted therapies have revolutionized cancer treatment, including the treatment strategy in mCRPC. Poly(adenosine 5ʹ-diphosphate) ribose polymerase inhibitors (PARPi) are oral drugs that target mutations in the homologous recombination repair (HRR) pathway, which are found in approximately 27% of prostate cancer patients. In May 2020, the first PARP inhibitor, olaparib, was approved by the US Food and Drug Administration for men with mCRPC with HHR gene mutations based on the findings of the Phase III PROfound trial that showed improved overall survival in men with mCRPC who received olaparib and whose disease had progressed on a novel hormonal agent. This review summarizes the current evidence and clinical utility of olaparib as treatment in men with mCRPC. We describe the mechanism of action of PARPi, key clinical trials of olaparib in men with mCRPC, and ongoing Phase II and III clinical trials investigating olaparib in combination therapy and as front-line therapy in mCRPC. Keywords: olaparib, PARP inhibitors, prostate cancer, DNA damage repair, homologous recombination repair Metastatic castration-resistant prostate cancer (mCRPC) is an aggressive and fatal disease with an estimated 34,130 deaths in the US in 2021 and a median survival of 36 months. 1,2 While metastatic prostate cancer is initially treated with androgen deprivation therapy (ADT), the majority of metastatic prostate cancers progress to mCRPC – a disease state which no longer responds to first-line ADT. There are a number of treatment options available for use in mCRPC, including taxanes, sipuleucel-T, abiraterone acetate, enzalutamide, and radium-223, but outcomes continue to remain poor due to progressive resistance to therapies. In the last decade, genetic sequencing has identified new molecular targets in prostate cancer in pathways that promote tumorigenesis and can be targeted therapeutically. In May 2020, the poly(ADP) ribose polymerase inhibitor (PARPi) olaparib (Lynparza, AstraZeneca Pharmaceuticals, LP) was granted approval by the US Food and Drug Administration (FDA) for use in mCRPC. 3 The purpose of this review is to describe the evidence and clinical utility of olaparib as treatment for men with mCRPC. We describe the mechanism of action of PARPi, key clinical trials which resulted in the FDA approval of olaparib, and current guidelines and administration recommendations. Next, we outline clinical trials of combination therapies with olaparib and conclude with ongoing clinical trials and areas for future research for the use of olaparib in mCRPC. The PARP family of enzymes repair DNA damage caused by single-stranded breaks (SSB) in DNA that arise from replication errors or damage from external agents such as radiation, free radicals/reactive oxygen species, or toxins. Mutations in prostate cancer are commonly found in DNA-damage repair (DDR) pathways, and when they occur in the homologous recombination repair (HRR) pathway specifically, tumors rely on poly(ADP) ribose polymerase (PARP) to correct DNA damage and prevent cell lysis. 4 PARP acts by repairing SSB in DNA and preventing progression to double-stranded breaks (DSB) by maintaining the integrity of the replication fork. 4 When SSB occur, PARP1 acts by recruiting the necessary proteins to repair DNA, including proteins to process the damaged DNA, the DNA polymerase which fills the gap, and DNA ligase III which seals the nick. When DSB occur, DNA is repaired by two major mechanisms: non-homologous end-joining (NHEJ) and HRR. 4 NHEJ repair involves the direct ligation of the fr -Abstract Truncated-
oncology,biotechnology & applied microbiology